CSPC Pharmaceutical Group Limited (CSPCY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in CSPC Pharmaceutical Group Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

CSPC Pharmaceutical Group Limited (CSPCY) has returned 6.96% so far this year and 86.13% over the past 12 months.

Based on dividend-adjusted daily data since Apr 8, 2019, CSPCY's average daily return is +0.24%, while the average monthly return is +4.80%. At this rate, your investment would double in approximately 1.2 years.

Historically, 48% of months were positive and 52% were negative. The best month was Aug 2019 with a return of +360.0%, while the worst month was Jul 2019 at -69.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CSPCY closed higher 41% of trading days. The best single day was Aug 1, 2019 with a return of +291.4%, while the worst single day was Jul 22, 2019 at -69.0%.

CSPC Pharmaceutical Group Limited has an annualized alpha of 78.78%, beta of 0.30, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 01, 2019.

• This stock captured 5.22% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -36.12%) — a profile typical of hedging or uncorrelated assets.
• Beta of 0.30 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CSPCY ranks 79 for risk / return — better than 79% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for CSPC Pharmaceutical Group Limited (CSPCY) and compare them to a chosen benchmark (S&P 500 Index).

CSPC Pharmaceutical Group Limited provided a 2.67% dividend yield over the last twelve months, with an annual payout of $0.12 per share.

The table displays the monthly dividend distributions for CSPC Pharmaceutical Group Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CSPC Pharmaceutical Group Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CSPC Pharmaceutical Group Limited was 69.41%, occurring on Jul 22, 2019. Recovery took 1 trading session.

The current CSPC Pharmaceutical Group Limited drawdown is 18.01%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CSPC Pharmaceutical Group Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CSPC Pharmaceutical Group Limited is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.